Please provide your email address to receive an email when new articles are posted on . A home-based cardiac rehabilitation program improved functional capacity and was associated with regaining ...
Use of a mobile app was not associated with better cardiac outcomes or completing a cardiac rehabilitation program. Prior studies have shown the potential of mobile apps in transforming cardiac rehab, ...
AT-001 (caficrestat) demonstrated a strong trend in stabilizing cardiac functional capacity, while the placebo group declined over 15 months AT-001 treatment resulted in a statistically significant ...
Compared with placebo, a significant improvement in cardiac functional capacity was observed among caficrestat-treated patients not receiving concomitant SGLT2is or GLP-1 RAs. Treatment with ...
NEW YORK, April 04, 2024 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular ...
THE WOODLANDS, Texas, Nov. 08, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that new sotagliflozin clinical data was presented at the AHA Annual Scientific ...
Camzyos is the first and only FDA-approved cardiac myosin inhibitor that specifically targets the source of obstructive HCM PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) today ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback